The ADOPT trial investigators have reported that 30 days of apixaban thromboprophylaxis is associated with a similar 30-day rate of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis as 6–14 days of enoxaparin (2.71% vs 3.06%; relative risk 0.87, 95% CI 0.62–1.23, P = 0.44) in medically ill patients. Furthermore, by day 30, apixaban was associated with more major bleeding than enoxaparin (0.47% vs 0.19%; relative risk 2.58, 95% CI 1.02–7.24, P = 0.04). However, the authors highlight that “the ADOPT trial was underpowered”, and believe that, “even though [the] trial was negative, the strategy of extended prophylaxis with apixaban may have promise”.